KINSHASA — The Democratic Republic of the Congo (DRC) has officially launched clinical trials for two experimental treatments targeting the Bundibugyo strain of the Ebola virus, marking a significant step in the ongoing effort to contain the disease.
On Thursday, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus confirmed that the first patient had received one of the two therapies currently under evaluation.
The clinical trial, spearheaded by the DRC’s National Institute of Biomedical Research (INRB), is being conducted with the support of a coalition of international partners, including the WHO. According to Dr. Tedros, the study is focused on two primary therapeutic approaches:
- Antibody-based therapy: Designed to neutralize the virus by utilizing specific proteins to mark the pathogen for destruction by the immune system.
- Antiviral drug: A pharmacological intervention aimed at inhibiting the virus’s ability to replicate within the human body.
Health officials emphasized that the trial is being conducted with rigorous safety standards. All patients participating in the study will receive comprehensive supportive care and will be under constant medical supervision to ensure their safety while researchers assess the efficacy of the treatments.
While the Ebola virus remains a significant public health threat in the region, medical experts hope that these trials will provide the necessary data to improve survival rates and develop a more effective standard of care for those infected with the Bundibugyo strain.
